Human plasma fibronectin (FN) enhances fibrin polymer strength and is typically present at <5% in fibrinogen (FI) surgical tissue sealants. We describe a purification process to obtain a mixture of γγ’ fibrinogen (γγ’FI) and FN at about the same mass concentration levels as occurs in plasma. Ammonium sulfate precipitation and DEAE chromatography of solvent-detergent treated plasma cryoprecipitate selectively concentrated γγ’FI and FN while effectively removing the γγFI component from FI. An interaction between γγ’FI and FN was observed by High Pressure Size Exclusion Chromatography (HPSEC) and Dynamic Light Scattering (DLS). A strong fibrin matrix was formed from treatment by a mixture of recombinant thrombin (rFIIa) and recombinant factor XIII (rFXIII). The γγ’FI and FN fibrin had an asymptotic shear elastic modulus strength observed by thromboelastography (TEG) of 16 kDynes/cm2 versus 9 kDynes/cm2 obtained from γγFI and FN. Confocal microscopy showed that the γγ’FI:FN fibrin matrix had a novel structure: γγ’FI fibers were periodically wrapped with FN aggregates. These studies provide a method for making a strong plasma-derived fibrin matrix having only 9 mg/ml total protein of γγ’FI, FN when polymerized at high levels of rFIIa and rFXIII activity.
- Fibrin sealants
- Recombinant factor XIII
- γγ’FI:FN mixture
ASJC Scopus subject areas
- Applied Microbiology and Biotechnology